Concord Biotech Ltd

Concord Biotech Bonus Issue

Concord Biotech allotted 10,46,16,204 bonus shares in a 1:1 ratio. Total equity shares rise to 20,92,32,408 after the bonus allotment.

Concord Biotech Earnings Call Transcript: Key Takeaways

Revenue grew 25% YoY driven by API demand, but gross margins contracted 400bps due to rising solvent costs and geopolitical disruptions.

Call

Guides 18% growth

Concord Biotech Investor Presentation: Key Takeaways

Q2FY27 consolidated revenue ₹309.1 Cr (+25%) and PAT ₹69.6 Cr (+10%); H1 revenue ₹566.6 Cr (+26%). Margins compressed; Inspira dermatology division launched.

Concord Biotech Bonus Issue

Concord Biotech fixed 4 November 2026 as the record date for a 1:1 bonus issue, with deemed allotment on 5 November 2026. The bonus is subject to statutory and regulatory approvals.

Concord Biotech Q2 FY27 Results: Net Profit ₹69.6 Cr, Up 10.3% YoY

Concord Biotech Ltd reported revenue from operations of ₹309.1 Cr (+25.1% YoY) and net profit of ₹69.6 Cr (+10.3% YoY) for Q2 FY27.

Key figure

Net profit ₹69.6 Cr · +10.3% YoY

Concord Biotech Bonus Issue

Concord Biotech's postal ballot approved a bonus issue and an authorised capital increase. No cash is paid and no ratio is stated.

Concord Biotech Board Meeting Date

Concord Biotech has scheduled its Q2 FY27 board meeting for 27 Oct 2026 to approve standalone and consolidated results. Trading window remains closed until 48 hours post result declaration.

Concord Biotech Other Announcement

Concord Biotech Ltd has filed its quarterly shareholding pattern under Regulation 31 for the period ended September 30, 2026.

Concord Biotech Bonus Issue

Concord Biotech's board recommended a 1:1 bonus share issue from free reserves. Shareholders will consider this proposal at an upcoming postal ballot on October 24, 2026.

Concord Biotech Bonus Issue

Concord Biotech approved a 1:1 bonus issue of 10.46 crore equity shares. The board also increased the company's authorized share capital to Rs. 22 Crore.

Value

₹10.46 Cr

Concord Biotech Board Meeting Date

Concord Biotech Ltd announced a board meeting for September 23, 2026, to consider a proposal for the declaration of bonus equity shares.

Concord Biotech Business Update

Concord Biotech disclosed a successful USFDA inspection at its Valthera facility with one minor non-GMP observation. No material impact on operations or existing supplies is expected.